AU2020322173A1 — Topical compositions
Assigned to Bausch Health Ireland Ltd · Expires 2022-02-17 · 4y expired
What this patent protects
The disclosure provides a topical gel formulation comprising 1-1.5 wt. % clindamycin phosphate, 2.5-3.5 wt.% benzoyl peroxide, and 0.1-0.2 wt.% adapalene, in combination with a gelling agent, a polyhydric alcohol, and water, useful in treating inflammatory skin conditions, includ…
USPTO Abstract
The disclosure provides a topical gel formulation comprising 1-1.5 wt. % clindamycin phosphate, 2.5-3.5 wt.% benzoyl peroxide, and 0.1-0.2 wt.% adapalene, in combination with a gelling agent, a polyhydric alcohol, and water, useful in treating inflammatory skin conditions, including acne, together with methods of making and using the same.
Drugs covered by this patent
- Differin (ADAPALENE) · Galderma Labs Lp
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.